Novel targets and therapeutic strategies for type 2 diabetes (Q35114594)

6 August 2017

1 reference

title

Novel targets and therapeutic strategies for type 2 diabetes (English)

1 reference

6 August 2017

1 reference

1 reference

https://api.crossref.org/works/10.1016/S1043-2760(03)00031-6

27 December 2023

1

Núria Morral

1 reference

PubMed ID

12714277

6 August 2017

language of work or name

1 reference

1 May 2003

1 reference

PubMed ID

12714277

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S1043276003000316?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1043-2760(03)00031-6

https://api.elsevier.com/content/article/PII:S1043276003000316?httpAccept=text/plain

27 December 2023

1 reference

https://api.crossref.org/works/10.1016/S1043-2760(03)00031-6

Trends in Endocrinology and Metabolism

27 December 2023

published in

1 reference

6 August 2017

14

1 reference

6 August 2017

4

1 reference

6 August 2017

169-175

1 reference

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Global and societal implications of the diabetes epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Pathophysiology of insulin resistance in human disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Safety of drugs commonly used to treat hypertension, dyslipidemia, and type 2 diabetes (the metabolic syndrome): part 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Insulin signalling and the regulation of glucose and lipid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

The hormone resistin links obesity to diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Resistin gene expression in human adipocytes is not related to insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

The lipid phosphatase SHIP2 controls insulin sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Missing pieces in the NF-kappaB puzzle

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Cell-specific Expression and Regulation of a Glucokinase Gene Locus Transgene

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Phenotypic correction of diabetic mice by adenovirus-mediated glucokinase expression

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Adenovirus-mediated expression of glucokinase in the liver as an adjuvant treatment for type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Increasing fructose 2,6-bisphosphate overcomes hepatic insulin resistance of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Elucidation of the role of fructose 2,6-bisphosphate in the regulation of glucose fluxes in mice using in vivo (13)C NMR measurements of hepatic carbohydrate metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Chlorogenic acid and hydroxynitrobenzaldehyde: new inhibitors of hepatic glucose 6-phosphatase.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Prolonged blood glucose reduction in mrp-2 deficient rats (GY/TR(-)) by the glucose-6-phosphate translocase inhibitor S 3025.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

GSK3, a master switch regulating cell-fate specification and tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

The renaissance of GSK3

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Lithium therapy and signal transduction.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Triglycerides, fatty acids and insulin resistance--hyperinsulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

A novel serum protein similar to C1q, produced exclusively in adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

AdipoQ is a novel adipose-specific gene dysregulated in obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1).

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Diet-induced insulin resistance in mice lacking adiponectin/ACRP30

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

AMP-activated protein kinase: the energy charge hypothesis revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

AMP-activated protein kinase (AMPK) is activated in muscle of subjects with type 2 diabetes during exercise

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Characterization of the role of the AMP-activated protein kinase in the stimulation of glucose transport in skeletal muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Role of AMP-activated protein kinase in mechanism of metformin action

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Adenovirus-mediated preproinsulin gene transfer into adipose tissues ameliorates hyperglycemia in obese diabetic KKA(y) mice

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

A transgenic model of visceral obesity and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900031-6

7 January 2021

AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes

series ordinal

62

1 reference

https://api.crossref.org/works/10.1016/S1043-2760(03)00031-6

27 December 2023

Identifiers

1 reference

6 August 2017

1 reference

PubMed ID

12714277